Document is current
Any future updates will be listed below
-
Authors
Mendez, Lucas C.
Dhar, Aneesh
Laidley, David
Moussa, Madeleine
Gomez, Jose A.
Chin, Joseph
Lee, T-Y
Thiessen, Jonathan D.
Hoover, Douglas
Surrey, Kathleen
Helou, Joelle
Velker, Vikram
Correa, Rohann J.
D’Souza, David
Bayani, Jane
Bauman, Glenn
- License Information
-
More Information
Article History
Received: 2 December 2022
Accepted: 14 April 2023
First Online: 20 April 2023
Declarations
:
: AD – none. GB – Industry Advisory Boards and Speaking – Tolmar, Trelstar, and Advanced Accelerator Applications; Industry Research – Siemens, and Invicro; Leadership – OICR Clinical Lead Clinical Translation Program, and OH-CCO PET Steering Committee; Research Funding – OICR, CIHR, and CCSRI. LCM – none. DL – none. MM – none. JAG – none. JC – none. T-Y L – none. JT – Industry Research – Siemens, Cubresa, and Invicro; Research Funding – NSERC, CFI, DoD, CRS, OICR, CIHR. DH – none. KS – none. JH – none. VV – none. RJC – none. DD?S – none. JB – none.
: This study has been approved by the Western University Health Sciences Research Ethics Board (Project ID: 120132) and will be conducted in accordance with the principles of the Declaration of Helsinki. Western University, located in London, Ontario, Canada, is the University partner of the London Health Sciences Centre, the academic hospital system of London, Ontario and the surrounding region. Patients will give their informed consent voluntarily to participate in this trial.
: Patients will give their consent voluntarily to have the results published.
